| Date Filed | Type | Description |
| 06/10/2022 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/07/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 06/07/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/03/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/03/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 06/02/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 05/31/2022 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 05/31/2022 |
4
| POWELL MICHAEL (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 30,000 options to buy
@ $5.19, valued at
$155.7k
Disposed/sold 10,030 options to buy
@ $6.27, valued at
$62.9k
Disposed/sold 30,000 options to buy
@ $10.95, valued at
$328.5k
|
|
| 05/31/2022 |
4
| Flaherty Keith T. (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 10,030 options to buy
@ $6.27, valued at
$62.9k
Disposed/sold 4,012 options to buy
@ $2.47, valued at
$9.9k
Disposed/sold 22,736 options to buy
@ $2.62, valued at
$59.6k
|
|
| 05/31/2022 |
4
| Isacoff Oren (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 10,030 options to buy
@ $6.27, valued at
$62.9k
Disposed/sold 20,000 options to buy
@ $10.95, valued at
$219k
|
|
| 05/31/2022 |
4
| Colabuono Peter (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 10,030 options to buy
@ $6.27, valued at
$62.9k
Disposed/sold 20,000 options to buy
@ $10.95, valued at
$219k
|
|
| 05/31/2022 |
4
| Yan Joy (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 20,061 options to buy
@ $3.12, valued at
$62.6k
|
|
| 05/31/2022 |
4
| Dolski Robert (CFO) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 101,180 options to buy
@ $2.05, valued at
$207.4k
Disposed/sold 27,300 options to buy
@ $5.09, valued at
$139k
Disposed/sold 150,000 options to buy
@ $14.84, valued at
$2.2M
|
|
| 05/31/2022 |
4
| Wooldridge James (Chief Medical Officer) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 54,600 options to buy
@ $13.5, valued at
$737.1k
Disposed/sold 101,180 options to buy
@ $2.05, valued at
$207.4k
Disposed/sold 27,300 options to buy
@ $5.09, valued at
$139k
Disposed/sold 150,818 options to buy
@ $15, valued at
$2.3M
Disposed/sold 95,916 options to buy
@ $2.62, valued at
$251.3k
|
|
| 05/31/2022 |
4
| Wigginton Jon Marc (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 20,061 options to buy
@ $2.19, valued at
$43.9k
|
|
| 05/31/2022 |
4
| Fuhrman Alan (Director) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 246,671 options to buy
@ $3.93, valued at
$969.4k
Disposed/sold 10,030 options to buy
@ $6.27, valued at
$62.9k
Disposed/sold 22,736 options to buy
@ $2.62, valued at
$59.6k
|
|
| 05/31/2022 |
4
| BASH ALAN (CEO) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 575,000 options to buy
@ $2.99, valued at
$1.7M
|
|
| 05/31/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/31/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/31/2022 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 05/31/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/31/2022 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 05/31/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/31/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/20/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/20/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
SC 14D9/A
| Form SC 14D9/A - Solicitation, recommendation statements: [Amend] |
| 05/11/2022 |
SC TO-T/A
| Form SC TO-T/A - Tender offer statement by Third Party: [Amend] |
| 05/11/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 05/09/2022 |
4
| venBio Global Strategic Fund II L.P. (10% Owner) has filed a Form 4 on Checkmate Pharmaceuticals, Inc.|
Txns:
| Sold 20,743 shares
@ $10.37, valued at
$215.1k
Sold 48,334 shares
@ $10.3702, valued at
$501.2k
Sold 17,600 shares
@ $10.374, valued at
$182.6k
|
|
|